Cost-effectiveness of Interferon Alfa-2b With and Without Ribavirin as Therapy for Chronic Hepatitis C in Sweden

By Sennfält K.   Reichard O.   Hultkrantz R.   Wong J. B.   Jonsson D.  

Scandinavian Journal of Gastroenterology, Vol. 36, Iss. 8, 2001-08 ,pp. : 870-876

Informa Healthcare

Access to resources Recommend Favorite

Prediction of Sustained Virological Response to Combination Therapy with Pegylated Interferon Alfa and Ribavirin in Patients with Genotype 3 Chronic Hepatitis C

By Tohra S.  

Digestive Diseases and Sciences, Vol. 56, Iss. 8, 2011-08 ,pp. : 2449-2455

Springer Publishing Company

Access to resources Recommend Favorite

Response to Combination Therapy with Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C According to a TNF-α Promoter Polymorphism

By  

Digestion, Vol. 68, Iss. 1, 2003-10 ,pp. : 1-4

Karger

Access to resources Recommend Favorite

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

By Takaki Shintaro   Tsubota Akihito   Hosaka Tetsuya   Akuta Norio   Someya Takashi   Kobayashi Masahiro   Suzuki Fumitaka   Suzuki Yoshiyuki   Saitoh Satoshi   Arase Yasuji   Ikeda Kenji   Kumada Hiromitsu  

Journal of Gastroenterology, Vol. 39, Iss. 7, 2004-07 ,pp. : 668-673

Springer Publishing Company

Access to resources Recommend Favorite

Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review

By Saito Masaya  

Clinical Journal of Gastroenterology, Vol. 5, Iss. 2, 2012-04 ,pp. : 119-126

Springer Publishing Company

Access to resources Recommend Favorite